Mon, Jul 28, 2014, 9:57 AM EDT - U.S. Markets close in 6 hrs 3 mins


% | $
Click the to save as a favorite.

MultiCell Technologies, Inc. Message Board

shabule 1 post  |  Last Activity: Jul 14, 2014 9:21 PM Member since: Jan 31, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • shabule by shabule Jul 14, 2014 9:21 PM Flag

    It is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease and over 500,000 patients are diagnosed annually, with nearly one in eight older Americans affected by the disease. Alzheimer's is the third leading cause of death in the United States. The estimated cost of unpaid care in the United States is estimated at over $210 billion annually and the total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. It is estimated that the cost to the United States will exceed $1.4 trillion by 2050. Amarantus believes the market opportunity for an effective Alzheimer's disease blood diagnostic such as LymPro far exceeds $500 million annually in the United States alone, and the Company intends to be first to market with a biologically relevant diagnostic blood test for Alzheimer's.

    This was posted in May of this year. Looking at these numbers, Lympro alone could easily get us over $1.00 and beyond in the very short term. The fact that some on this board are toping it off at $.40 or $.50 are discounting it imo. With all the data becoming known of late, and all the major players becoming more aware or Lympro potential, the sky is the limit. The amount of impact a legit blood test for detection of alzheimers both financially and medically worldwide is enormous. Amarantus will be the first to market such a product, so don't be too shocked if this flies high very soon.

    Sentiment: Strong Buy

0.0007-0.0001(-12.50%)9:30 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.